Skip to search formSkip to main contentSkip to account menu

LU 208075

Known as: LU-208075, LU208075 
National Institutes of Health

Related topics

Related topics

2 relations
BSF 208075

Broader (1)

ambrisentan

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
Endothelin Antagonism Prevents Diabetic Retinopathy in NOD Mice: A Potential Role of the Angiogenic Factor Adrenomedullin
Altered activity of retinal endothelin-1 (ET-1) and nitric oxide may play a causal role in the hemodynamic and histopathological… 
2003
2003
Cerebrovascular Characterization of the Novel Nonpeptide Endothelin-A Receptor Antagonist LU 208075
Enhanced cerebrovascular resistance under pathologic conditions, like cerebral vasospasm after subarachnoid hemorrhage, seems to… 
2002
2002
Effect of the novel endothelin(A) receptor antagonist LU 208075 on contraction and relaxation of isolated rat basilar artery.
Increased levels of endothelin (ET)-1 and bigET-1 may be responsible for enhanced cerebroarterial resistance under pathologic… 
Review
2002
Review
2002
Ambrisentan (Myogen).
Ambrisentan (LU-208075, BSF-208075) and LU-302146 (BSF-302146) are being developed by Myogen, under license from Abbott (formerly… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)